UofL to develop and test nasal spray to prevent COVID-19

(University of Louisville) The University of Louisville has received funding from the U.S. Department of Defense to develop a nasal spray to prevent serious viral respiratory infections such as COVID-19 using Q-Griffithsin, a drug compound developed and co-owned by UofL. The one-year project, funded through an $8.5 million agreement from the DoD, includes developing the spray, testing the formulation in lab studies and conducting a Phase I clinical trial.